Long-Term Oral Toxicity and Anti-osteoporotic Effect of Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal Osteoporosis

Yuh Feng Tsai, Li Ho Hsu, Chang Chin Wu, Wei Hua Cai, Kai Chiang Yang, Fang Yu Fan

Research output: Contribution to journalArticle

Abstract

Sintered dicalcium pyrophosphate (SDCP), a synthetic pyrophosphate analog, has shown potential for the management of osteoporosis. The long-term oral toxicity and anti-osteoporotic effect of SDCP in a postmenopausal osteoporosis rat model were evaluated in this study. SDCP was orally administered to bilateral ovariectomized (OVX) Wistar rats at a dose of 0.75 mg/kg daily for 24 weeks following by 2 weeks of observation. There were no abnormal findings in clinical signs of toxicity, food consumption, body weight, blood examination, necropsy, and histological inspection attributable to the ingestion of SDCP. The serum level of type I collagen fragments, a bone resorption marker, decreased in SDCP-treated rats, and the bone formation markers alkaline phosphatase, osteocalcin, and osteopontin significantly decreased. These findings indicate that the bone turnover rate decreased in SDCP-treated animals. Relative to OVX rats, the increase in serum tartrate-resistant acid phosphatase 5b level represents an increase in bony tissues in the SDCP-treated rats. Histological examinations of distal femoral metaphyses further revealed that the ingestion of SDCP improved the trabecular bone architecture and decreased bone porosity. Analysis of limb bone ashes showed a significant increase in bone mineral content. Our results show that SDCP inhibits bone resorption to restore bone mass in OVX rats without deleterious effects, and therefore that SDCP has potential in the management of osteoporosis.

Original languageEnglish
Pages (from-to)181-190
Number of pages10
JournalJournal of Medical and Biological Engineering
Volume37
Issue number2
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Postmenopausal Osteoporosis
Toxicity
Rats
Bone
Phosphatases
Ashes
Bone Resorption
Osteoporosis
diphosphoric acid
Eating
Bone and Bones
Osteopontin
Collagen
Bone Remodeling
Porosity
Osteocalcin
Collagen Type I
Thigh
Serum
Animals

Keywords

  • Bone turnover markers
  • Oral toxicity
  • Osteoporosis
  • Pyrophosphate analog
  • Sintered dicalcium pyrophosphate

ASJC Scopus subject areas

  • Medicine(all)
  • Biomedical Engineering

Cite this

Long-Term Oral Toxicity and Anti-osteoporotic Effect of Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal Osteoporosis. / Tsai, Yuh Feng; Hsu, Li Ho; Wu, Chang Chin; Cai, Wei Hua; Yang, Kai Chiang; Fan, Fang Yu.

In: Journal of Medical and Biological Engineering, Vol. 37, No. 2, 01.04.2017, p. 181-190.

Research output: Contribution to journalArticle

@article{ac69d79b4d2e4b86b4d71c393bc86b29,
title = "Long-Term Oral Toxicity and Anti-osteoporotic Effect of Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal Osteoporosis",
abstract = "Sintered dicalcium pyrophosphate (SDCP), a synthetic pyrophosphate analog, has shown potential for the management of osteoporosis. The long-term oral toxicity and anti-osteoporotic effect of SDCP in a postmenopausal osteoporosis rat model were evaluated in this study. SDCP was orally administered to bilateral ovariectomized (OVX) Wistar rats at a dose of 0.75 mg/kg daily for 24 weeks following by 2 weeks of observation. There were no abnormal findings in clinical signs of toxicity, food consumption, body weight, blood examination, necropsy, and histological inspection attributable to the ingestion of SDCP. The serum level of type I collagen fragments, a bone resorption marker, decreased in SDCP-treated rats, and the bone formation markers alkaline phosphatase, osteocalcin, and osteopontin significantly decreased. These findings indicate that the bone turnover rate decreased in SDCP-treated animals. Relative to OVX rats, the increase in serum tartrate-resistant acid phosphatase 5b level represents an increase in bony tissues in the SDCP-treated rats. Histological examinations of distal femoral metaphyses further revealed that the ingestion of SDCP improved the trabecular bone architecture and decreased bone porosity. Analysis of limb bone ashes showed a significant increase in bone mineral content. Our results show that SDCP inhibits bone resorption to restore bone mass in OVX rats without deleterious effects, and therefore that SDCP has potential in the management of osteoporosis.",
keywords = "Bone turnover markers, Oral toxicity, Osteoporosis, Pyrophosphate analog, Sintered dicalcium pyrophosphate",
author = "Tsai, {Yuh Feng} and Hsu, {Li Ho} and Wu, {Chang Chin} and Cai, {Wei Hua} and Yang, {Kai Chiang} and Fan, {Fang Yu}",
year = "2017",
month = "4",
day = "1",
doi = "10.1007/s40846-016-0197-x",
language = "English",
volume = "37",
pages = "181--190",
journal = "Journal of Medical and Biological Engineering",
issn = "1609-0985",
publisher = "中華民國生物醫學工程學會",
number = "2",

}

TY - JOUR

T1 - Long-Term Oral Toxicity and Anti-osteoporotic Effect of Sintered Dicalcium Pyrophosphate in Rat Model of Postmenopausal Osteoporosis

AU - Tsai, Yuh Feng

AU - Hsu, Li Ho

AU - Wu, Chang Chin

AU - Cai, Wei Hua

AU - Yang, Kai Chiang

AU - Fan, Fang Yu

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Sintered dicalcium pyrophosphate (SDCP), a synthetic pyrophosphate analog, has shown potential for the management of osteoporosis. The long-term oral toxicity and anti-osteoporotic effect of SDCP in a postmenopausal osteoporosis rat model were evaluated in this study. SDCP was orally administered to bilateral ovariectomized (OVX) Wistar rats at a dose of 0.75 mg/kg daily for 24 weeks following by 2 weeks of observation. There were no abnormal findings in clinical signs of toxicity, food consumption, body weight, blood examination, necropsy, and histological inspection attributable to the ingestion of SDCP. The serum level of type I collagen fragments, a bone resorption marker, decreased in SDCP-treated rats, and the bone formation markers alkaline phosphatase, osteocalcin, and osteopontin significantly decreased. These findings indicate that the bone turnover rate decreased in SDCP-treated animals. Relative to OVX rats, the increase in serum tartrate-resistant acid phosphatase 5b level represents an increase in bony tissues in the SDCP-treated rats. Histological examinations of distal femoral metaphyses further revealed that the ingestion of SDCP improved the trabecular bone architecture and decreased bone porosity. Analysis of limb bone ashes showed a significant increase in bone mineral content. Our results show that SDCP inhibits bone resorption to restore bone mass in OVX rats without deleterious effects, and therefore that SDCP has potential in the management of osteoporosis.

AB - Sintered dicalcium pyrophosphate (SDCP), a synthetic pyrophosphate analog, has shown potential for the management of osteoporosis. The long-term oral toxicity and anti-osteoporotic effect of SDCP in a postmenopausal osteoporosis rat model were evaluated in this study. SDCP was orally administered to bilateral ovariectomized (OVX) Wistar rats at a dose of 0.75 mg/kg daily for 24 weeks following by 2 weeks of observation. There were no abnormal findings in clinical signs of toxicity, food consumption, body weight, blood examination, necropsy, and histological inspection attributable to the ingestion of SDCP. The serum level of type I collagen fragments, a bone resorption marker, decreased in SDCP-treated rats, and the bone formation markers alkaline phosphatase, osteocalcin, and osteopontin significantly decreased. These findings indicate that the bone turnover rate decreased in SDCP-treated animals. Relative to OVX rats, the increase in serum tartrate-resistant acid phosphatase 5b level represents an increase in bony tissues in the SDCP-treated rats. Histological examinations of distal femoral metaphyses further revealed that the ingestion of SDCP improved the trabecular bone architecture and decreased bone porosity. Analysis of limb bone ashes showed a significant increase in bone mineral content. Our results show that SDCP inhibits bone resorption to restore bone mass in OVX rats without deleterious effects, and therefore that SDCP has potential in the management of osteoporosis.

KW - Bone turnover markers

KW - Oral toxicity

KW - Osteoporosis

KW - Pyrophosphate analog

KW - Sintered dicalcium pyrophosphate

UR - http://www.scopus.com/inward/record.url?scp=85017163303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017163303&partnerID=8YFLogxK

U2 - 10.1007/s40846-016-0197-x

DO - 10.1007/s40846-016-0197-x

M3 - Article

AN - SCOPUS:85017163303

VL - 37

SP - 181

EP - 190

JO - Journal of Medical and Biological Engineering

JF - Journal of Medical and Biological Engineering

SN - 1609-0985

IS - 2

ER -